Federal Register / Vol. 87, No. 80 / Tuesday, April 26, 2022 / Notices 24569 

1Title XXXIII of the PHS Act is codified at 42 

U.S.C. 300mm to 300mm-61. Those portions of the 

James Zadroga 9/11 Health and Compensation Act 

of 2010 found in Titles II and III of Public Law 111– 

347 do not pertain to the WTC Health Program and 

are codified elsewhere. 

2The List of WTC-Related Health Conditions is 

established in 42 U.S.C. 300mm-22(a)(3)–(4) and 

300mm-32(b); additional conditions may be added 

through rulemaking and the complete list is 

provided in WTC Health Program regulations at 42 

CFR 88.15. 

diagnosing and treating health 

conditions on the List of WTC-Related 

Health Conditions. 

DATES: Comments must be received by 

May 26, 2022. 

ADDRESSES: Comments may be 

submitted through either of the 

following methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov (follow the 

instructions for submitting comments), 

or 

• By Mail: NIOSH Docket Office, 

Robert A. Taft Laboratories, MS: C–34, 

1090 Tusculum Avenue, Cincinnati, 

Ohio 45226–1998. Attn: Docket No. 

CDC–2022–0055; NIOSH–348. 

Instructions: All written submissions 

received in response to this notice must 

include the agency name (Centers for 

Disease Control and Prevention, HHS) 

and docket number (CDC–2022–0055; 

NIOSH–348) for this action. All relevant 

comments, including any personal 

information provided, will be posted 

without change to http://

www.regulations.gov. Do not submit 

comments by email. CDC does not 

accept comments by email. 

FOR FURTHER INFORMATION CONTACT: 

Rachel Weiss, Program Analyst, 1090 

Tusculum Avenue, MS: C–46, 

Cincinnati, Ohio 45226; Telephone: 

(404) 498–2500 (this is not a toll-free 

number); Email NIOSHregs@cdc.gov. 

SUPPLEMENTARY INFORMATION: Title I of 

the James Zadroga 9/11 Health and 

Compensation Act of 2010 (Pub. L. 111– 

347, as amended by Pub. L. 114–113 

and Pub. L. 116–59), added Title XXXIII 

to the Public Health Service (PHS) Act,1

establishing the WTC Health Program 

within HHS. The WTC Health Program 

provides medical monitoring and 

treatment benefits for certified health 

conditions on the List of WTC-Related 

Health Conditions 2 to eligible 

firefighters and related personnel, law 

enforcement officers, and rescue, 

recovery, and cleanup workers who 

responded to the September 11, 2001, 

terrorist attacks in New York City, at the 

Pentagon, and in Shanksville, 

Pennsylvania (responders). The Program 

also provides benefits to eligible persons 

who were present in the dust or dust 

cloud on September 11, 2001, or who 

worked, resided, or attended school, 

childcare, or adult daycare in the New 

York City disaster area (survivors). 

The Zadroga Act also requires that the 

Program establish a research program on 

health conditions resulting from the 

September 11, 2001, terrorist attacks, 

addressing the following topics: 

• Physical and mental health 

conditions that may be related to the 

September 11, 2001, terrorist attacks; 

• Diagnosing WTC-related health 

conditions for which there have been 

diagnostic uncertainty; and 

• Treating WTC-related health 

conditions for which there have been 

treatment uncertainty. 

Request for Information 

Lifestyle medicine is a highly 

valuable, evidence-informed clinical 

approach focused on managing and 

reversing many of the types of chronic 

diseases certified by the WTC Health 

Program. By focusing on sustainable 

health behaviors and lifestyle factors, 

including six pillars—nutrition and 

diet, sleep hygiene, stress management 

and positive psychology, physical 

activity, social connectedness, and 

avoidance of substance misuse— 

lifestyle medicine has the potential to 

limit disease progression, to prevent 

development of additional chronic 

diseases, and to improve health 

outcomes, overall member well-being, 

quality of life, and member satisfaction 

with the Program. 

To establish the scope of the WTC 

Health Program FY2023 lifestyle 

medicine research, NIOSH seeks to 

achieve a suitable mix of projects and 

interventions focusing on sustainable 

health behaviors and the lifestyle 

factors, described above. All these 

influence quality of life, disease 

progression and recurrence, survival, 

adverse events, and other health-related 

outcomes among WTC Health Program 

members. Specifically, NIOSH seeks 

input on the following questions 

pertaining to WTC Health Program 

research priorities: 

(1) What are the primary lifestyle 

research needs of both responders and 

survivors? 

(2) What are the primary health 

outcomes associated with WTC-related 

health conditions that lifestyle research 

interventions should target? 

(3) What are the most important 

lifestyle factors (e.g., nutrition and diet, 

sleep hygiene, stress management and 

positive psychology, physical activity, 

social connectedness, cognitive 

function, and avoidance of substance 

misuse) that need to be addressed 

within the scope of the research 

solicitation? 

John J. Howard, 

Administrator, World Trade Center Health 

Program and Director, National Institute for 

Occupational Safety and Health, Centers for 

Disease Control and Prevention, Department 

of Health and Human Services. 

[FR Doc. 2022–08817 Filed 4–25–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifiers: CMS–10409] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, and to allow 

a second opportunity for public 

comment on the notice. Interested 

persons are invited to send comments 

regarding the burden estimate or any 

other aspect of this collection of 

information, including the necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions, the accuracy of 

the estimated burden, ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and the use 

of automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments on the collection(s) of 

information must be received by the 

OMB desk officer by May 26, 2022. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 


jspears on DSK121TN23PROD with NOTICES1
24570 Federal Register / Vol. 87, No. 80 / Tuesday, April 26, 2022 / Notices 

for Public Comments’’ or by using the 

search function. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ website address at 

website address at: https://

www.cms.gov/Regulations-andGuidance/Legislation/ 

PaperworkReductionActof1995/PRAListing.html. 

FOR FURTHER INFORMATION CONTACT: 

William Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. The term ‘‘collection of 

information’’ is defined in 44 U.S.C. 

3502(3) and 5 CFR 1320.3(c) and 

includes agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: LTCH CARE 

Data Set for the Collection of Data 

Pertaining to the Long-Term Care 

Hospital Quality Reporting Program; 

Use: We are requesting an extension to 

the Long-Term Care Hospital Continuity 

Assessment Record and Evaluation Data 

Set (LTCH CARE Data Set or LCDS) 

Version 5.0 that will be effective on 

October 1, 2022. 

On November 2, 2021 the Centers for 

Medicare & Medicaid Services (CMS) 

issued a final rule (86 FR 62240) which 

finalized proposed modifications to the 

effective date for the reporting of 

measures and certain standardized 

patient assessment data in the Longterm Care Hospital Quality Reporting 

Program (LTCH QRP). Per the final rule 

CMS will require LTCHs to start 

collecting assessment data using LCDS 

Version 5.0 beginning October 1, 2022. 

The information collection request for 

LCDS Version 5.0 was re-approved on 

December 7, 2021 with an October 1, 

2022 implementation date. CMS is 

asking for an extension of the approved 

LCDS Version 5.0, which currently 

expires on December 31, 2022. 

The LTCH CARE Data Set is used to 

collect, submit, and report quality data 

to CMS for compliance with the LongTerm Care Hospital Quality Reporting 

Program (LTCH QRP). Form Number: 

CMS–10409 (OMB control number: 

0938–1163); Frequency: Occasionally; 

Affected Public: Private Sector: Business 

or other for-profit and not-for-profit 

institutions; Number of Respondents: 

415; Total Annual Responses: 204,936; 

Total Annual Hours: 145,831. (For 

policy questions regarding this 

collection contact Christy Hughes at 

410–786–5662.) 

Dated: April 20, 2022. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2022–08823 Filed 4–25–22; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Neurological Sciences 

Training Initial Review Group NST–1 Study 

Section (NST–1 Clinician K Application 

Review). 

Date: May 23–24, 2022. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: William C. Benzing, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS, NIH, NSC, 6001 Executive 

Boulevard, Suite 3204, MSC 9529, Bethesda, 

MD 20892–9529, 301–496–0660, benzingw@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: April 20, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08833 Filed 4–25–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Engineered Tumor 

Infiltrating Lymphocytes for Cancer 

Therapy 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this Notice to Iovance 

Biotherapeutics, Inc. (‘‘Iovance’’), 

headquartered in San Carlos, CA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before May 11, 2022 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Andrew Burke, Ph.D., 

Senior Technology Transfer Manager, 

NCI Technology Transfer Center, 

Telephone: (240)-276–5484; Email: 

andy.burke@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

E–170–2009: Inducible Interleukin-12 

1. US Provisional Patent Application 

61/174,046, filed April 30, 2009 (E–170– 

2009–0–US–01); 

2. International Patent Application 

PCT/US2010/031988, filed April 22, 

2010 (E–170–2009–0–PCT–02); 


jspears on DSK121TN23PROD with NOTICES1